Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1ion Mar 23, 2024 9:14am
230 Views
Post# 35948619

mdj...my thoughts and logic on history repeating itself....

mdj...my thoughts and logic on history repeating itself....Pfizer, $6.4 Billion for Arena Pharma...small cannabinoid pharma pipeline
Pfizer, +$50 Billion for Seagen....targeted payload delivery

LABS....pharmaceutical supplier of cannabinoid compounds to the likes of Arena and Seagen

History repeating itself?  Astrazeneca taking out FUSN and their targeted payload delivery tech

How will history repeat itself for LABS????  

Pfizer has a division that supplies active pharma molecules to other pharma companies but they do NOT have active pharma molecules based on cannabinoids....it is the missing piece of the puzzle for Pfizer and Bourla's comment of 1 out of 3 will get cancer in conjunction with the FDA stating clearly that cannabinoids have applications to treat cancer.
<< Previous
Bullboard Posts
Next >>